GlassScriptPhysician profile
Clyde O Green
NPI 1417178187
$15,151.75
in general payments reported to CMS, 2019-2025
62 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,587 · 2020: $2,335 · 2021: $2,070 · 2022: $2,116 · 2023: $1,811 · 2024: $1,406 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,932 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,931.96 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,608.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,031.15 | 2019-2025 | |
| Novo Nordisk INC | $808.71 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $746.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $690.28 | 2023-2025 | Gemtesa, Aptiom |
| Glaxosmithkline, LLC. | $627.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $603.82 | 2019-2025 | |
| Amgen INC. | $566.56 | 2019-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $538.88 | 2021-2025 | |
| Lundbeck LLC | $520.39 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $475.01 | 2021-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $463.99 | 2019-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $426.21 | 2019-2022 | |
| Allergan, INC. | $399.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.41 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.